4/3
02:04 am
omer
Omeros Co. (NASDAQ: OMER) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Omeros Co. (NASDAQ: OMER) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
4/2
11:32 am
omer
Omeros Corporation (NASDAQ:OMER) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Omeros Corporation (NASDAQ:OMER) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
4/1
04:10 pm
omer
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results [Yahoo! Finance]
Medium
Report
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results [Yahoo! Finance]
4/1
04:02 pm
omer
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results
Medium
Report
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results
3/27
08:30 am
omer
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
Low
Report
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
3/26
11:02 pm
omer
Omeros Co. (NASDAQ: OMER) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Omeros Co. (NASDAQ: OMER) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
2/20
09:38 am
omer
Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy [Yahoo! Finance]
Low
Report
Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy [Yahoo! Finance]
2/20
09:00 am
omer
Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
Medium
Report
Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
2/11
01:00 am
omer
Omeros Co. (NASDAQ: OMER) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Omeros Co. (NASDAQ: OMER) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
2/3
01:07 am
omer
Omeros Co. (NASDAQ: OMER) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Omeros Co. (NASDAQ: OMER) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
2/1
09:43 am
omer
DRI Healthcare Trust Announces the Expansion of its Royalty Entitlement on the US Net Sales of Omidria®, Updates Deployment and CAGR Guidance [Yahoo! Finance]
Low
Report
DRI Healthcare Trust Announces the Expansion of its Royalty Entitlement on the US Net Sales of Omidria®, Updates Deployment and CAGR Guidance [Yahoo! Finance]
2/1
09:13 am
omer
Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust [Yahoo! Finance]
Low
Report
Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust [Yahoo! Finance]
2/1
09:11 am
omer
Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust
Medium
Report
Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust
1/26
10:34 pm
omer
Omeros Co. (NASDAQ: OMER) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Omeros Co. (NASDAQ: OMER) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.